Sarepta Therapeutics, Inc. (SRPT) Stock Score, Valuation & Financial Research
Sarepta Therapeutics, Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 35/100.
Quick answer for SRPT
Sarepta Therapeutics, Inc. currently has a Wall Street Score of 35/100. The stored market price is $20.85. Its financial score is 25/100. Its valuation score is 0/100. These figures are a research snapshot, not a buy or sell recommendation.
What Sarepta Therapeutics, Inc. does
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company dedicated to the discovery and advancement of genetic treatment modalities, including RNA-targeted therapeutics and gene therapies, specifically for rare diseases. The company currently offers two approved treatments: EXONDYS 51, prescribed for Duchenne muscular dystrophy (DMD) patients with confirmed dystrophin gene mutations amenable to exon 51 skipping, and VYONDYS 53, for DMD patients with exon 53 skipping mutations. Sarepta's development pipeline includes AMONDYS 45, an exon-skipping product candidate utilizing phosphorodiamidate morpholino oligomer chemistry for exon 45; SRP-5051, a peptide-conjugated PMO designed to target exon 51 of dystrophin pre-mRNA; and gene therapy programs such as SRP-9001 for DMD and SRP-9003 for limb-girdle muscular dystrophies. The company maintains collaborative agreements with o
SRPT financial snapshot
- Wall Street Score:
- 35/100
- Current price:
- $20.85
- Market capitalization:
- $2.20B
- Revenue:
- $2.18B
- Net income:
- $65.1M
- Free cash flow:
- $-307.5M
- Cash:
- $464.4M
- Total debt:
- $1.04B
- EPS:
- -7.13
- Financial score:
- 25/100
- Valuation score:
- 0/100
- Revenue score:
- 38/100
What stands out
- Reported year-over-year revenue growth is -0.0%.
- Free cash flow is $-307.5M, showing cash burn in the current stored period.
- The balance sheet shows $464.4M of cash versus $1.04B of total debt, so leverage deserves attention.
What the numbers mean
Its current valuation score is 0/100, which Wall Street Score classifies as weak within the model's valuation framework.
The financial score is 25/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-07-24.
How to research SRPT
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.